<DOC>
	<DOCNO>NCT01889303</DOCNO>
	<brief_summary>Concurrent chemoradiotherapy demonstrate significant improvement overall survival disease-free survival accord Intergroup Trial 0116 patient gastric cancer surgical resection . However , still many patient experience local recurrence distant metastasis adjuvant chemotherapy concurrent chemoradiotherapy locally advance gastric cancer resection . The optimal standard regimen adjuvant treatment establish locally advanced gastric cancer yet.The investigator design trial investigate efficacy safety docetaxel plus cisplatin regimen adjuvant chemotherapy concurrent chemoradiotherapy regimen compare classical FOLFOX6 regimen adjuvant chemotherapy 5-FU/CF chemoradiotherapy patient locally advanced gastric cancer D2 radical resection .</brief_summary>
	<brief_title>Phase II Study DC Versus 5-FU/CF Chemotherapy Concurrent Chemoradiotherapy Locally Advanced Gastric Cancer</brief_title>
	<detailed_description>In Intergroup 0116 trial , 5-FU plus CF regimen use adjuvant chemotherapy concurrent chemoradiotherapy patient resect gastric cancer.But 33 percent chemoradiotherapy group distant relapse . Docetaxel plus cisplatin regimen adjuvant chemotherapy gastric cancer proof Safe Effective many clinical trial gastric cancer . The purpose study evaluate efficacy safety docetaxel plus cisplatin regimen adjuvant chemotherapy concurrent chemoradiotherapy regimen compare classical FOLFOX6 regimen adjuvant chemotherapy 5-FU/CF chemoradiotherapy patient locally advanced gastric cancer D2 radical surgery . The investigator hope new intervention reduce rate distant metastasis clinical benefit .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Written inform consent 2 . Age &gt; 19 3 . Histologically proven gastric gastroesophageal adenocarcinoma 4 . ≥ D2 lymph node dissection , curative gastrectomy , 5 . Stage T4 without positive LN ( AJCC 2010 ) ，No distant metastasis ( M0 ) D2 radical gastrectomy 6 . KPS≥70 ECOG 02 7 . R0 resection , 8 . Adequate bone marrow function ( WBC≥4.0×109/L，GRAN≥2.0×109/L，Hb≥90g/L , transfusion allow , PLT≥100×109/L ) 9 . No severe functional damage major organ , uncontrolled severe cardiopulmonary concurrent system disease 10 . Adequate renal function ( serum creatinine ≤ 1.5×ULN ) ; liver function ( serum bilirubin ≤ 1.5×ULN , AST/ALT ≤ 2.5 time ( normal value ) , serum AKP≤2.5×ULN 11 . Predictive survival time longer 6 month . 1. pregnant breastfeed woman ; 2 . Have receive preoperative neoadjuvant therapy gastric cancer 3 . Before time malignant tumor , underwent chemotherapy , immune , biological treatment radiation therapy ; exception adequately treat cervical carcinoma situ localize nonmelanoma skin cancer 4. uncontrolled mental disease 5 . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV , myocardial infarction within last 12 month , unstable angina pectoris , significant arrhythmia ) 6 . Active infection require antibiotic 7 . Resection margin ( + ) permanent pathology 8 . Peripheral neuropathy symptom , NCI class &gt; 1 9. severe malnutrition severe anemia 10. uncontrolled Primary brain tumor central nervous system disease 11 . Known hypersensitivity study drug 12 . Pathologic stage IIIa IV ( accord AJCC 2010 ) 13 . Inadequate surgery include D0 , D1 resection , dissect LNs le 12 14 . Concurrent treatment experimental drug anticancer therapy , treatment within clinical trial within 30 day prior trial entry</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>FOLFOX6</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>gastric cancer</keyword>
</DOC>